ProKidney Corp. Class A (PROK)

ProKidney Corp.'s stock has been impacted by several events in the past six months. The stock saw a decrease following the appointment of Greg Madison as Chief Commercial Officer and after reporting its full-year 2025 financial results. The stock increased after announcing its presentation at the 44th Annual J.P. Morgan Healthcare Conference and after reporting its third-quarter 2025 financial results. The stock rose after presenting full results from the Phase 2 REGEN-007 trial of Rilparencel at the American Society of Nephrology Kidney Week 2025. The stock experienced a surge following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study. Overall, the stock has gained 154.9% over the past 12 months.

As a clinical-stage biotechnology company, ProKidney Corp. does not experience traditional product demand seasonality. Demand is currently driven by the progress and outcomes of its clinical studies and regulatory approvals rather than seasonal consumer patterns. The company targets a significant unmet medical need, with a substantial potential market upon regulatory approval.

ProKidney Corp. is a late clinical-stage biotechnology company focused on developing cellular therapies for chronic kidney disease (CKD). The company's primary business involves pioneering autologous cell therapy to preserve kidney function in patients with advanced CKD and type 2 diabetes. Its lead product candidate is rilparencel, a first-in-class autologous cellular therapy derived from a patient's own renal cells, currently in Phase 3 clinical trials and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

ProKidney Corp. is headquartered in Winston-Salem, North Carolina, United States. The company conducts its clinical trials predominantly in the United States, with additional sites in Asia and Latin America.

ProKidney Corp.'s brand reputation has been shaped by its clinical progress and regulatory interactions. The company has maintained a positive public perception due to positive results from its Phase 2 REGEN-007 study and alignment with the FDA on an accelerated approval pathway for rilparencel. Analyst ratings are generally positive, with a consensus of "Moderate Buy" from several firms. However, the company faces inherent risks such as regulatory unpredictability, significant cash outflow, and reliance on a single experimental treatment.

ProKidney Corp. has a mixed ownership structure, including institutional, retail, and individual investors. Approximately 51.59% of the stock is held by institutions. Insiders own about 18.92% of the company's stock, and individual investors hold a significant 32% stake. Pablo Legorreta is the company's largest shareholder with 17% of shares outstanding.